+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost effectiveness analysis of antenatal HIV screening in United Kingdom

Cost effectiveness analysis of antenatal HIV screening in United Kingdom

Bmj 319(7219): 1230-1234

To assess the cost effectiveness of universal antenatal HIV screening compared with selective screening in the United Kingdom. Incremental cost effectiveness analysis relating additional costs of screening to life years gained. Maternal and paediatric costs and life years were combined. United Kingdom. Number of districts for which universal screening would be cost effective compared with selective screening under various conditions. On base case assumptions, a new diagnosis of a pregnant woman with HIV results in a gain of 6.392 life years and additional expenditure of 14 833 pounds. If decision makers are prepared to pay up to 10 000 pounds an additional life year, this would imply a net benefit of 49 090 pounds (range 12 300 pounds- 59 000 pounds), which would be available to detect each additional infected woman in an antenatal screening programme. In London, universal antenatal screening would be cost effective compared with a selective screening under any reasonable assumptions about screening costs. Outside London, universal screening with uptake above 90% would be cost effective with a 0.60 pounds HIV antibody test cost and up to 3.5 minutes for pretest discussion. Cost effectiveness of universal testing is lower if selective testing can achieve high uptake among those at higher risk. A universal strategy with only 50% uptake may not be less cost effective in low prevalence districts and may cost more and be less effective than a well run selective strategy. Universal screening with pretest discussion should be adopted throughout the United Kingdom as part of routine antenatal care as long as test costs can be kept low and uptake high.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 045660580

Download citation: RISBibTeXText

PMID: 10550083

DOI: 10.1136/bmj.319.7219.1230

Related references

Strategic options for antenatal screening for syphilis in the United Kingdom: a cost effectiveness analysis. Journal of Medical Screening 7(1): 7, 2000

Cost-effectiveness of digital photographic screening for retinopathy of prematurity in the United Kingdom. International Journal of Technology Assessment in Health Care 20(2): 201-213, 2004

Cost effectiveness of antenatal screening for cystic fibrosis. Realistic cost must be established for genetic counselling in two step screening. Bmj 312(7035): 908; Author Reply 910, 1996

Alarming resistance of Neisseria gonorrhoeae in a tertiary care hospital of North India. Indian Journal of Medical Microbiology 36(2): 285-288, 2018

Abobotulinumtoxin A In The Management of Cervical Dystonia In The United Kingdom: A Cost-Effectiveness Analysis. Value in Health 18(7): A757-A758, 2015

Cost effectiveness of antenatal screening for cystic fibrosis. Study might be better described as a cost description of screening. Bmj 312(7035): 909-910, 1996

A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom. Health Economics Review 3(1): 18, 2013

Expanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United Kingdom. Plos one 9(4): E95735, 2014

Antenatal syphilis screening using point-of-care testing in Sub-Saharan African countries: a cost-effectiveness analysis. Plos Medicine 10(11): E1001545, 2013

Performance of antenatal HIV screening strategies in the United Kingdom. Journal of Medical Screening 5(3): 133-136, 1998

Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Annals of PharmacoTherapy 40(10): 1752-1758, 2006

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom. Journal of Medical Economics 16(10): 1246-1254, 2013

Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom. Genomic Medicine 1(1-2): 35-45, 2007

Antenatal ultrasound screening for fetal abnormalities: a systematic review of studies of cost and cost effectiveness. Bjog 109(1): 44-56, 2002

Antenatal syphilis screening using point-of-care testing in low- and middle-income countries in Asia and Latin America: a cost-effectiveness analysis. Plos one 10(5): E0127379, 2015